Search research articles
Contact Us
Filters
Showing results (51-60 of 66) with videos related to
Page
of 7
Sort By:
Cancers
|
February 11, 2021
Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer
Arturo Araujo, Leah M Cook, Jeremy S Frieling, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
May 26, 2011
Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone
Jeffry S Nyman, Conor C Lynch, Daniel S Perrien, et al.
JBMR Plus
|
April 19, 2021
EphA2 Is a Clinically Relevant Target for Breast Cancer Bone Metastatic Disease
David B Vaught, Alyssa R Merkel, Conor C Lynch, et al.
Cancer Research
|
February 2, 2021
Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival
Chen Hao Lo, Gemma Shay, Jeremy J McGuire, et al.
Cancer Cell
|
May 17, 2005
MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL
Conor C Lynch, Atsuya Hikosaka, Heath B Acuff, et al.
Science Translational Medicine
|
June 28, 2019
Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer
Ning Zhao, Stephanie O Peacock, Chen Hao Lo, et al.
Nature Communications
|
March 20, 2024
The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease
Ryan T Bishop, Anna K Miller, Matthew Froid, et al.
Haematologica
|
December 5, 2024
Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed/refractory multiple myeloma
Ryan T Bishop, Tao Li, Praneeth Sudalagunta, et al.
Molecular Cancer Therapeutics
|
March 25, 2017
Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
Stuart W Ember, Que T Lambert, Norbert Berndt, et al.
Science Advances
|
May 3, 2023
γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer
Jeremy S Frieling, Leticia Tordesillas, Xiomar E Bustos, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 66) with videos related to
Sort By:
Page
of 7
Cancers
|
February 11, 2021
Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer
Arturo Araujo, Leah M Cook, Jeremy S Frieling, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
May 26, 2011
Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone
Jeffry S Nyman, Conor C Lynch, Daniel S Perrien, et al.
JBMR Plus
|
April 19, 2021
EphA2 Is a Clinically Relevant Target for Breast Cancer Bone Metastatic Disease
David B Vaught, Alyssa R Merkel, Conor C Lynch, et al.
Cancer Research
|
February 2, 2021
Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival
Chen Hao Lo, Gemma Shay, Jeremy J McGuire, et al.
Cancer Cell
|
May 17, 2005
MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL
Conor C Lynch, Atsuya Hikosaka, Heath B Acuff, et al.
Science Translational Medicine
|
June 28, 2019
Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer
Ning Zhao, Stephanie O Peacock, Chen Hao Lo, et al.
Nature Communications
|
March 20, 2024
The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease
Ryan T Bishop, Anna K Miller, Matthew Froid, et al.
Haematologica
|
December 5, 2024
Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed/refractory multiple myeloma
Ryan T Bishop, Tao Li, Praneeth Sudalagunta, et al.
Molecular Cancer Therapeutics
|
March 25, 2017
Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
Stuart W Ember, Que T Lambert, Norbert Berndt, et al.
Science Advances
|
May 3, 2023
γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer
Jeremy S Frieling, Leticia Tordesillas, Xiomar E Bustos, et al.
Page
of 7